← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
IPOD
COLLECTIVE ACQUISITION CORP.
Valuation N/A
Financial Services
Price$10.45
Model IV—
P/IV—
Limited data — see page
IPST
IP STRATEGY HOLDINGS, INC.
Valuation N/A
Consumer Defensive Risk 31 · Moderate
Price$3.05
Model IV—
P/IV—
Market implies +25.8%/yr vs model +12.7% · above model
IPWR
Ideal Power Inc.
Valuation N/A
Technology Risk 30 · Moderate
Price$4.79
Model IV—
P/IV—
Market implies +121.3%/yr vs model +2.0% · above model
IPX
IPERIONX Ltd
Valuation N/A
Basic Materials Risk 42 · Elevated
Price$18.67
Model IV—
P/IV—
Limited data — see page
IQ
iQIYI, Inc.
Valuation N/A
Communication Services Risk 55 · Elevated
Price$1.00
Model IV—
P/IV—
Limited data — see page
IQI
Invesco Quality Municipal Income Trust
Valuation N/A
Unknown
Price$9.85
Model IV—
P/IV—
Limited data — see page
IRAB
Iris Acquisition Corp II
Valuation N/A
Financial Services
Price$10.00
Model IV—
P/IV—
Limited data — see page
IREN
IREN Ltd
Valuation N/A
Financial Services Risk 41 · Elevated
Price$43.17
Model IV—
P/IV—
Market implies +82.2%/yr vs model +15.0% · above model
IRHO
Iron Horse Acquisition II Corp.
Valuation N/A
Financial Services Risk 29 · Moderate
Price$10.06
Model IV—
P/IV—
Limited data — see page
IRHOR
Iron Horse Acquisition II Corp.
Valuation N/A
Financial Services Risk 42 · Elevated
Price$0.17
Model IV—
P/IV—
Limited data — see page
IRON
Disc Medicine, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$70.06
Model IV—
P/IV—
Limited data — see page
IRS
IRSA INVESTMENTS & REPRESENTATIONS INC
Valuation N/A
Real Estate Risk 58 · Elevated
Price$15.36
Model IV—
P/IV—
Limited data — see page
ISD
PGIM High Yield Bond Fund, Inc.
Valuation N/A
Unknown
Price$12.11
Model IV—
P/IV—
Limited data — see page
ISOU
IsoEnergy Ltd.
Valuation N/A
Basic Materials Risk 52 · Elevated
Price$10.64
Model IV—
P/IV—
Limited data — see page
ISPC
iSpecimen Inc.
Valuation N/A
Industrials Risk 43 · Elevated
Price$1.33
Model IV—
P/IV—
Market implies +22.0%/yr vs model +2.0% · above model
ITHA
ITHAX Acquisition Corp III
Valuation N/A
Financial Services
Price$10.06
Model IV—
P/IV—
Limited data — see page
ITOC
iTonic Holdings Ltd
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.30
Model IV—
P/IV—
Market implies +56.3%/yr vs model +2.0% · above model
ITRG
Integra Resources Corp.
Valuation N/A
Basic Materials Risk 34 · Moderate
Price$2.76
Model IV—
P/IV—
Limited data — see page
ITUB
Itau Unibanco Holding S.A.
Valuation N/A
Financial Services Risk 59 · Elevated
Price$8.33
Model IV—
P/IV—
Limited data — see page
IVA
Inventiva S.A.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$4.02
Model IV—
P/IV—
Limited data — see page
IVF
INVO Fertility, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$0.97
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
IVVD
Invivyd, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$0.79
Model IV—
P/IV—
Market implies +21.5%/yr vs model +15.0% · above model
IWDL
UBS AG
Valuation N/A
Financial Services Risk 47 · Elevated
Price$70.25
Model IV—
P/IV—
Limited data — see page
IWFL
UBS AG
Valuation N/A
Financial Services Risk 33 · Moderate
Price$61.44
Model IV—
P/IV—
Limited data — see page
IWML
UBS AG
Valuation N/A
Financial Services Risk 52 · Elevated
Price$34.49
Model IV—
P/IV—
Limited data — see page
IXHL
Incannex Healthcare Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$3.26
Model IV—
P/IV—
Market implies +123.1%/yr vs model +15.0% · above model
JACS
Jackson Acquisition Co II
Valuation N/A
Financial Services
Price$10.76
Model IV—
P/IV—
Limited data — see page
JAGU
Jaguar Uranium Corp.
Valuation N/A
Basic Materials Risk 27 · Moderate
Price$1.56
Model IV—
P/IV—
Market implies +49.8%/yr vs model +5.0% · above model
JAN
Janus Living, Inc.
Valuation N/A
Financial Services
Price$31.59
Model IV—
P/IV—
Limited data — see page
JANX
Janux Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$17.10
Model IV—
P/IV—
Market implies +55.1%/yr vs model +28.8% · above model
JATT
JATT II Acquisition Corp.
Valuation N/A
Financial Services Risk 51 · Elevated
Price$12.25
Model IV—
P/IV—
Limited data — see page
JBIO
Jade Biosciences, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$17.89
Model IV—
P/IV—
Limited data — see page
JBK
LEHMAN ABS CORP GOLDMAN SACHS CAP 1 SEC BACKED SER 2004-6
Valuation N/A
Financial Services
Price$25.32
Model IV—
P/IV—
Limited data — see page
JBS
JBS N.V.
Valuation N/A
Consumer Defensive
Price$12.28
Model IV—
P/IV—
Limited data — see page
JCAP
Jefferson Capital, Inc. / DE
Valuation N/A
Financial Services Risk 60 · High
Price$21.38
Model IV—
P/IV—
Market implies -23.1%/yr vs model +25.0% · below model
JCE
Nuveen Core Equity Alpha Fund
Valuation N/A
Unknown
Price$16.85
Model IV—
P/IV—
Limited data — see page
JCTC
JEWETT CAMERON TRADING CO LTD
Valuation N/A
Consumer Cyclical Risk 42 · Elevated
Price$2.88
Model IV—
P/IV—
Market implies +45.0%/yr vs model +0.0% · above model
JEF
Jefferies Financial Group Inc.
Valuation N/A
Financial Services Risk 39 · Moderate
Price$51.96
Model IV—
P/IV—
Market implies +67.0%/yr vs model +2.0% · above model
JENA
JENA ACQUISITION Corp II
Valuation N/A
Financial Services
Price$10.48
Model IV—
P/IV—
Limited data — see page
JF
J & Friends Holdings Ltd
Valuation N/A
Technology Risk 41 · Elevated
Price$0.95
Model IV—
P/IV—
Market implies +89.8%/yr vs model +12.0% · above model
JFR
NUVEEN FLOATING RATE INCOME FUND
Valuation N/A
Unknown
Price$7.60
Model IV—
P/IV—
Limited data — see page
JG
Aurora Mobile Ltd
Valuation N/A
Technology
Price$6.50
Model IV—
P/IV—
Limited data — see page
JGH
Nuveen Global High Income Fund
Valuation N/A
Unknown
Price$12.20
Model IV—
P/IV—
Limited data — see page
JHI
JOHN HANCOCK INVESTORS TRUST
Valuation N/A
Unknown
Price$12.61
Model IV—
P/IV—
Limited data — see page
JHS
JOHN HANCOCK INCOME SECURITIES TRUST
Valuation N/A
Unknown
Price$10.60
Model IV—
P/IV—
Limited data — see page
JHX
James Hardie Industries plc
Valuation N/A
Industrials Risk 57 · Elevated
Price$27.06
Model IV—
P/IV—
Market implies +34.2%/yr vs model +7.1% · above model
JKS
JinkoSolar Holding Co., Ltd.
Valuation N/A
Technology Risk 37 · Moderate
Price$11.35
Model IV—
P/IV—
Market implies +21.4%/yr vs model +8.0% · above model
JLS
Nuveen Mortgage & Income Fund/MA/
Valuation N/A
Unknown
Price$16.82
Model IV—
P/IV—
Limited data — see page
JMIA
Jumia Technologies AG
Valuation N/A
Consumer Cyclical Risk 37 · Moderate
Price$7.45
Model IV—
P/IV—
Limited data — see page
JMM
Nuveen Multi-Market Income Fund
Valuation N/A
Unknown
Price$5.68
Model IV—
P/IV—
Limited data — see page
JOBY
Joby Aviation, Inc.
Valuation N/A
Industrials Risk 35 · Moderate
Price$6.30
Model IV—
P/IV—
Market implies +82.0%/yr vs model +15.0% · above model
JOF
JAPAN SMALLER CAPITALIZATION FUND INC
Valuation N/A
Unknown
Price$12.56
Model IV—
P/IV—
Limited data — see page
JOYY
JOYY Inc.
Valuation N/A
Technology Risk 38 · Moderate
Price$77.26
Model IV—
P/IV—
Market implies +49.8%/yr vs model +7.0% · above model
JPC
Nuveen Preferred & Income Opportunities Fund
Valuation N/A
Unknown
Price$7.07
Model IV—
P/IV—
Limited data — see page
JQC
Nuveen Credit Strategies Income Fund
Valuation N/A
Unknown
Price$4.71
Model IV—
P/IV—
Limited data — see page
JRI
Nuveen Real Asset Income & Growth Fund
Valuation N/A
Unknown
Price$11.62
Model IV—
P/IV—
Limited data — see page
JRS
NUVEEN REAL ESTATE INCOME FUND
Valuation N/A
Unknown
Price$8.06
Model IV—
P/IV—
Limited data — see page
JSPR
Jasper Therapeutics, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.66
Model IV—
P/IV—
Limited data — see page
JTAI
Jet.AI Inc.
Valuation N/A
Industrials Risk 42 · Elevated
Price$1.28
Model IV—
P/IV—
Market implies +64.8%/yr vs model +2.0% · above model
JUNS
JUPITER NEUROSCIENCES, INC.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$3.05
Model IV—
P/IV—
Market implies +135.9%/yr vs model +15.0% · above model